<p>The Council of Scientific & Industrial Research (CSIR), in collaboration with Laxai Life Sciences Pvt Ltd, Hyderabad, has sought regulatory approval to undertake controlled phase III clinical trial using a combination of three different drugs to treat Covid-19 patients, a statement said on Tuesday.</p>.<p>The purpose behind the clinical trial is to rationally combine and repurpose antivirals and determine safety and efficacy of the three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA).</p>.<p>The clinical trial named MUCOVIN, to be carried out in partnership with Medanta Medicity, will include a total of 300 patients in four different groups of 75 each. The trials will be conducted for 17 to 21 days including screening and treatment, the statement said.</p>.<p>Shekhar Mande, director general of the CSIR, said each group of patients will be administered one set of drugs. </p>.<p>This unique combinatorial strategy (antivirals and HDTs) with repurposed drugs having complementary, additive and synergistic roles, has been adopted to increase therapeutic options for Covid-19 treatment and help recover patients faster, he said.</p>.<p>On CSIR's part, its two institutes -- Indian Institute of Chemical Technology, Hyderabad and Indian Institute of Integrative Medicine, Jammu -- are part of the exercise.</p>.<p>Ram S Upadhayaya, CEO, Laxai Life Sciences said the study aims to target viral proteins essential for its replication as well as host factors that play a crucial role in the viral life cycle and contribute to the cytokine storm.</p>.<p>Since the outbreak of the Covid-19 pandemic, the CSIR has been repurposing several drugs to check their efficacy for treating the coronavirus patients. </p>
<p>The Council of Scientific & Industrial Research (CSIR), in collaboration with Laxai Life Sciences Pvt Ltd, Hyderabad, has sought regulatory approval to undertake controlled phase III clinical trial using a combination of three different drugs to treat Covid-19 patients, a statement said on Tuesday.</p>.<p>The purpose behind the clinical trial is to rationally combine and repurpose antivirals and determine safety and efficacy of the three combination drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA).</p>.<p>The clinical trial named MUCOVIN, to be carried out in partnership with Medanta Medicity, will include a total of 300 patients in four different groups of 75 each. The trials will be conducted for 17 to 21 days including screening and treatment, the statement said.</p>.<p>Shekhar Mande, director general of the CSIR, said each group of patients will be administered one set of drugs. </p>.<p>This unique combinatorial strategy (antivirals and HDTs) with repurposed drugs having complementary, additive and synergistic roles, has been adopted to increase therapeutic options for Covid-19 treatment and help recover patients faster, he said.</p>.<p>On CSIR's part, its two institutes -- Indian Institute of Chemical Technology, Hyderabad and Indian Institute of Integrative Medicine, Jammu -- are part of the exercise.</p>.<p>Ram S Upadhayaya, CEO, Laxai Life Sciences said the study aims to target viral proteins essential for its replication as well as host factors that play a crucial role in the viral life cycle and contribute to the cytokine storm.</p>.<p>Since the outbreak of the Covid-19 pandemic, the CSIR has been repurposing several drugs to check their efficacy for treating the coronavirus patients. </p>